Who are Strattera (atomoxetine)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SPN-812 (600mg, QD), LY2216684 (edivoxetine).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/strattera-atomoxetine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Strattera (atomoxetine) — Competitive Intelligence Brief

Strattera (atomoxetine) (Strattera (atomoxetine)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective norepinephrine reuptake inhibitor (NRI). Area: Psychiatry/Neurology.

marketed Selective norepinephrine reuptake inhibitor (NRI) Norepinephrine transporter (NET) Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Strattera (atomoxetine) (Strattera (atomoxetine)) — Massachusetts General Hospital. Atomoxetine selectively inhibits the reuptake of norepinephrine in the brain, increasing norepinephrine levels in key attention and executive function circuits.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Strattera (atomoxetine) TARGET	Strattera (atomoxetine)	Massachusetts General Hospital	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
SPN-812 (600mg, QD)	SPN-812 (600mg, QD)	Supernus Pharmaceuticals, Inc.	marketed	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)
LY2216684 (edivoxetine)	LY2216684 (edivoxetine)	Eli Lilly and Company	phase 3	Selective norepinephrine reuptake inhibitor (NRI)	Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective norepinephrine reuptake inhibitor (NRI) class)

Eli Lilly and Company · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
Supernus Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Strattera (atomoxetine) — Competitive Intelligence Brief. https://druglandscape.com/ci/strattera-atomoxetine. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab